Research Article Details
| Article ID: | A52595 |
| PMID: | 25190687 |
| Source: | Nutr Clin Pract |
| Title: | Nutrition status of patients with chronic hepatitis B or C. |
| Abstract: | OBJECTIVE: Nutrition disorders in patients with chronic liver disease have become a recent concern because these disorders influence outcomes. We investigated patients' nutrition status, included consecutively in the last 2 years to the study, and related the results with the severity of liver disease. METHODS: A total of 230 patients with hepatitis B (n = 80) or C (n = 150) were evaluated by the subjective global assessment (SGA) and body mass index (BMI). The risk of metabolic complications was assessed by waist circumference (WC) and the percentage of body fat (%BF). Alcohol abuse was defined as daily consumption >20 g and >30 g for women and men, respectively. RESULTS: The mean age was 54 years, with 52.6% women, 75% patients without cirrhosis, and 15% patients with cirrhosis. According to the SGA, 86.5% of patients were nourished, and 13.5% were malnourished. Malnutrition was associated with cirrhosis (prevalence ratio [PR], 1.25; 95% confidence interval [CI], 1.1-1.4; P < .001), alcohol abuse, direct bilirubin >3.0 mg/dL, international normalized ratio >1.1, platelet <150 × 10(3)/mm(3), hemoglobin <12 g/dL, and serum albumin <3.5 g/dL (P < .05). According to the BMI, 43.9% of patients were eutrophic, 33.5% were overweight, 21.3% were obese, and 1.3% were underweight. Obese patients had a higher prevalence of steatosis than eutrophic (PR, 1.53; 95% CI, 1.15-2.04; P = .003) and overweight (PR, 1.71; 95% CI, 1.33-2.20; P < .001) patients. Overweight/obesity was associated with WC >94 cm (men) and >80 cm (women), %BF >25% (men) and >32% (women) (P < .01), triglyceride >150 mg/dL, high-density lipoprotein cholesterol <40 mg/dL, glucose >99 mg/dL, insulin >20 µU/mL, homeostatic model assessment-insulin resistance >3.2, and thyroid-stimulating hormone >2.5 µU/mL (P < .05). CONCLUSIONS: Overweight/obesity is prevalent among patients with hepatitis B and C and can contribute to the development of steatosis. Malnutrition is also observed and is related to the severity of liver disease. |
| DOI: | 10.1177/0884533614546168 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |